How to manage patients with corticosteroids in oncology in the era of immunotherapy?
Fiche publication
Date publication
novembre 2020
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MANSI Laura
Tous les auteurs :
Aldea M, Orillard E, Mansi L, Marabelle A, Scotte F, Lambotte O, Michot JM
Lien Pubmed
Résumé
Corticosteroids are among the most prescribed drugs in oncology. The indications range from cancer-related indications for refractory symptoms, anti-cancer effects mainly in hematology, supportive measures for cancer-specific treatments and more recently immune-related adverse events induced by modern immunotherapies. In oncological emergencies, corticosteroids are common first-line treatments because of their rapid effect and wide variety of actions. In the last 5 years, with the advance of immune checkpoint inhibitors, corticosteroids are becoming routinely used to manage immune-related adverse effects. Preclinical studies suggested that corticosteroid-induced immunosuppression might dampen the activity of immunotherapies. Prospective clinical studies show that corticosteroid use is a prognostic marker for the cancer outcome in metastatic setting but does not significantly alter the patient's response to immunotherapies per se. Here, we review the state of the art on corticosteroid use in oncology, with a focus on the drugs' potential impact on immunotherapy activity. The comprehensive pharmacological characteristics of corticosteroid drugs, clinical indications, modality of administration and associated precautions for use are discussed in this article.
Mots clés
Cancer, Corticosteroid, Immune-related adverse event, Immunotherapy, T-cell lymphocyte
Référence
Eur J Cancer. 2020 Nov 16;141:239-251